Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-01-02
2007-01-02
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C514S475000, C514S478000, C514S588000
Reexamination Certificate
active
10962333
ABSTRACT:
The present invention provides methods of treating an autoimmune disorder (e.g., lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis and diabetes mellitus) in a subject by administering to the subject a therapeutically effective amount of one or more compounds of the invention.
REFERENCES:
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5180735 (1993-01-01), Kishimoto et al.
patent: 5180738 (1993-01-01), Kishimoto et al.
patent: 5290807 (1994-03-01), Folkman et al.
patent: 5422363 (1995-06-01), Yanai et al.
patent: 5648382 (1997-07-01), Billington et al.
patent: 5698586 (1997-12-01), Kishimoto et al.
patent: 5767293 (1998-06-01), Oku et al.
patent: 5789405 (1998-08-01), Oku et al.
patent: 6017954 (2000-01-01), Folkman et al.
patent: 6086865 (2000-07-01), Folkman et al.
patent: 6584847 (2003-07-01), Hirose
patent: 6919307 (2005-07-01), Olson et al.
patent: 2002/0151493 (2002-10-01), Olson et al.
patent: 2002/0193298 (2002-12-01), Olson et al.
patent: 0354767 (1990-02-01), None
patent: 0357061 (1990-03-01), None
patent: 0359036 (1990-03-01), None
patent: 0387650 (1990-09-01), None
patent: 0415294 (1991-03-01), None
patent: 0658342 (1995-06-01), None
patent: WO-98/13059 (1998-04-01), None
patent: WO-98/56372 (1998-12-01), None
patent: WO-99/56686 (1999-11-01), None
patent: W0-99/61432 (1999-12-01), None
patent: WO-00/64486 (2000-11-01), None
patent: WO-00/69472 (2000-11-01), None
De Marre, Anne et al, “Synthesis and evaluation of macromolecular prodrugs of mitomycin C,”Journal of Controlled Release, vol. 36:87-97 (1995).
Denmeade, Samuel R. ET al, “Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen,”Cancer Research, vol. 58:2537-2540 (1998).
Griffith, Eric C. et al, “Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin,”Chemistry & Biology, vol. 4:461-471 (1997).
Griffith, Eric C. et al, “Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2,”Proc. Natl. Acad. Sci. USA, vol. 95:15183-15188 (1998).
Kyu Han, Cheol et al, “Design and Synthesis of Highly Potent Fumagillin Analogues from Homology Modeling for a Human MetAP-2,”Bioorganic & Medicinal Chemistry, vol. 10:39-10:43 (2000).
Landquist, Justus K., “Some Degradation Products of Fumagillin,”Journal of The Chemical Society, pp. 4237-4245 (1956).
Liu, Shenping et al, “Structure of Human Methionine Aminopeptidase-2 Complexed with Fumagillin,”Science, vol. 282:1324-1327 (1998).
Nichifor, Marieta et al, “Chemical and enzymatic hydrolysis of dipeptide derivatives of 5-fluorouracil,”Journal of Controlled Release, vol. 47:271-281 (1997).
Sin, Ny et al, “The anti-angiogenic agent fumagillin covalently binds and inhabits the methionine aminopeptidase, MetAP-2,”Proc. Natl. Acad. Sci. USA, vol. 94:6099-6103 (1997).
Tarbell et al, “The Structure of Fumagillin,”Journal of the American Society, vol. 82(4):1005-1007 (1960).
Timár, F. et al, “The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site,”Cancer Chemother Pharmacol, vol. 41:292-298 (1998).
Turk, Benjamin E. et al, “Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells,”Chemistry & Biology, vol. 6:823-833 (1999).
Zhang, Peng et al, “Angiogenesis Inhibitors Specific for Methionine Aminopeptidase 2 as Drugs for Malaria and Leishmaniasis,”Journal of Biomedical Science, vol. 9:34-40 (2002).
Arico-Muendel Christopher C.
Birktoft Jens
Cook Charles M.
Lee Lily
Morgan Barry
DeConti, Jr. Giulio A.
Laccotripe Zacharakis Maria
Lahive & Cockfield LLP
Praecis Pharmaceuticals Inc.
Russel Jeffrey Edwin
LandOfFree
Therapeutic agents and methods of use thereof for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents and methods of use thereof for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents and methods of use thereof for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3814006